Novavax Inc (NVAX): Price Up $1.25 (0.7)% Over Past Day, Down $-4.55 (-2.46)% Over Past Hour

The Hourly View for NVAX

500 – Internal server error This is a reversal of the price action on the previous hour, in which price moved up. As for the trend on the hourly timeframe, we see the clearest trend on the 100 hour timeframe. Regarding moving averages, it should first be noted that price has crossed the 20 and 50 hour moving averages, resulting in them so that price is now turning below them. The moving averages on the hourly timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment — meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend.

NVAX ranks 38th in terms of today’s price percentage change out of Pharmaceutical Products stocks.

NVAX’s Technical Outlook on the Daily Chart

At the time of this writing, NVAX’s price is up $1.25 (0.7%) from the day prior. This is a reversal of the price action on the previous day, in which price moved down. If you’re a trader with a preference for rangebound markets, you may wish to note that there isn’t a clear trend on the 20, 50 and 100 day timeframes. The moving averages on the daily timeframe suggest a choppiness in price, as the 20, 50, 100 and 200 are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders. Novavax Inc’s price action over the past 90 days can be seen via the chart below.

NVAX

<

NVAX: Daily RSI Analysis

  • For NVAX, its RSI is now at 11.4364.
  • NVAX and RSI both have consistent trends, as they are both heading down.

For NVAX News Traders

News traders keeping an eye on NVAX may find value in this recent story:

How Novavax Could Shake Up the COVID Vaccine Market

Moderna (NASDAQ: MRNA), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) and its partner BioNTech (NASDAQ: BNTX) share the U.S. COVID-19 vaccine market right now. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss how Novavax (NASDAQ: NVAX) could potentially shake up the COVID vaccine market.

Want More Great Investing Ideas?

9 “MUST OWN” Growth Stocks for 2021

5 WINNING Stock Chart Patterns

7 Best ETFs for the NEXT Bull Market